MIRA Pharmaceuticals Selects Neuropathic Pain As Initial And Primary Indication For Its Novel Oral Ketamine Analog, Ketamir-2; Submits Request For Pre-IND Meeting With FDA
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals has chosen neuropathic pain as the primary indication for its new oral ketamine analog, Ketamir-2. The company has requested a pre-IND meeting with the FDA, expected in November 2024, and plans to submit its IND by the end of this year, with human trials starting in Q1 2025.
September 11, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals is advancing its novel oral ketamine analog, Ketamir-2, targeting neuropathic pain. The company is on track for a pre-IND meeting with the FDA in November 2024 and plans to submit its IND by the end of this year, with human trials expected in Q1 2025.
The news indicates significant progress in MIRA's drug development pipeline, with clear timelines for regulatory meetings and trial commencement. This is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100